Omission of Axillary Surgery in Breast Cancer Patients

The treatment and prognosis of breast cancer (BC) are dependent on its molecular subtype and nodal burden. In early BCs with favourable molecular subtype, the incidence of axillary node involvement is low. However, these patients are still subjected to an axillary operation, which can result in additional cost, operating time and morbidities. Similarly, in patients with limited nodal burden of 1-2 metastatic nodes, there is emerging evidence that these patients may need sentinel lymph node biopsy (SLNB) only, instead of an axillary clearance (AC), which has more surgical morbidities. We aimed

Trial Details

NCT ID

NCT06259513

Phase

NA

Sponsor

KK Women's and Children's Hospital

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO

Locations (sample)

• Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

• female patients aged \>/=55 years old
• unifocal cancer on imaging
• breast tumour size based on imaging of \</=3cm
• no evidence of axillary adenopathy on imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →